VILMA RANGEL: Open Payments
NPI 1033684642 · WOODBURN, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$620 in 12 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $646 · 2025 $620
Food & beverage: $620
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $159 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| ABBVIE INC. | 1 | $114 |
| Lundbeck LLC | 1 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $71 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: REXULTI, CAPLYTA, VRAYLAR, AUSTEDO XR, UZEDY, Auvelity, Jornay PM, ARISTADA.
Industry payments across OR — which companies pay providers there.
